185 related articles for article (PubMed ID: 21098574)
1. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
[TBL] [Abstract][Full Text] [Related]
2. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
[TBL] [Abstract][Full Text] [Related]
3. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
5. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
7. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.
Bugatti S; Manzo A; Benaglio F; Klersy C; Vitolo B; Todoerti M; Sakellariou G; Montecucco C; Caporali R
Arthritis Res Ther; 2012 Feb; 14(1):R34. PubMed ID: 22336440
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
Szodoray P; Alex P; Dandapani V; Nakken B; Pesina J; Kim X; Wallis GL; Wilson PC; Jonsson R; Centola M
Scand J Immunol; 2004; 60(1-2):209-18. PubMed ID: 15238091
[TBL] [Abstract][Full Text] [Related]
11. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics.
De La Torre I; Leandro MJ; Valor L; Becerra E; Edwards JC; Cambridge G
Rheumatology (Oxford); 2012 May; 51(5):833-40. PubMed ID: 22253030
[TBL] [Abstract][Full Text] [Related]
12. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
Julià A; Barceló M; Erra A; Palacio C; Marsal S
Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
[TBL] [Abstract][Full Text] [Related]
14. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
[TBL] [Abstract][Full Text] [Related]
15. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.
Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318
[TBL] [Abstract][Full Text] [Related]
17. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced, extremity-dedicated MRI identifies synovitis changes in the follow-up of rheumatoid arthritis patients treated with rituximab.
Cimmino MA; Parodi M; Zampogna G; Boesen M; Kubassova O; Barbieri F; Paparo F; Garlaschi G; Cutolo M
Clin Exp Rheumatol; 2014; 32(5):647-52. PubMed ID: 25068921
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
20. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
